Literature DB >> 23613022

[Application of ultrahigh-field MRI in neuro-oncology].

A Radbruch1, H-P Schlemmer.   

Abstract

The introduction of high-field magnetic resonance imaging (MRI) into neuro-oncological imaging allows improved visualization of tumor structures even in the field of T1 and T2-weighted imaging. Susceptibility-weighted imaging (SWI) and time of flight (TOF) angiography in particular greatly benefit from the high field strength. The visualization of tumor vasculature in MRI, which was made possible by high-field technology can potentially be applied to monitoring antiangiogenic therapy. Cerebral metastases can potentially be discovered earlier using high-field technology. Furthermore, high-field technology permits the use of new technologies, such as sodium imaging, which is expected to provide new information in the field of tumor pathophysiology.

Entities:  

Mesh:

Year:  2013        PMID: 23613022     DOI: 10.1007/s00117-012-2347-7

Source DB:  PubMed          Journal:  Radiologe        ISSN: 0033-832X            Impact factor:   0.635


  22 in total

1.  High-resolution BOLD venographic imaging: a window into brain function.

Authors:  J R Reichenbach; E M Haacke
Journal:  NMR Biomed       Date:  2001 Nov-Dec       Impact factor: 4.044

2.  Ex vivo MR spectroscopic measure differentiates tumor from treatment effects in GBM.

Authors:  Radhika Srinivasan; Joanna J Phillips; Scott R Vandenberg; Mei-Yin C Polley; Gabriela Bourne; Alvin Au; Andrea Pirzkall; Soonmee Cha; Susan M Chang; Sarah J Nelson
Journal:  Neuro Oncol       Date:  2010-07-20       Impact factor: 12.300

3.  7-Tesla susceptibility-weighted imaging to assess the effects of radiotherapy on normal-appearing brain in patients with glioma.

Authors:  Janine M Lupo; Cynthia F Chuang; Susan M Chang; Igor J Barani; Bert Jimenez; Christopher P Hess; Sarah J Nelson
Journal:  Int J Radiat Oncol Biol Phys       Date:  2011-10-12       Impact factor: 7.038

Review 4.  Malignant gliomas in adults.

Authors:  Patrick Y Wen; Santosh Kesari
Journal:  N Engl J Med       Date:  2008-07-31       Impact factor: 91.245

5.  MR spectroscopy of the human brain with enhanced signal intensity at ultrashort echo times on a clinical platform at 3T and 7T.

Authors:  Ralf Mekle; Vladimír Mlynárik; Giulio Gambarota; Martin Hergt; Gunnar Krueger; Rolf Gruetter
Journal:  Magn Reson Med       Date:  2009-06       Impact factor: 4.668

6.  Longitudinal brain imaging of five malignant glioma patients treated with bevacizumab using susceptibility-weighted magnetic resonance imaging at 7 T.

Authors:  Günther Grabner; Iris Nöbauer; Katarzyna Elandt; Claudia Kronnerwetter; Adelheid Woehrer; Christine Marosi; Daniela Prayer; Siegfried Trattnig; Matthias Preusser
Journal:  Magn Reson Imaging       Date:  2011-10-06       Impact factor: 2.546

7.  Fractal analysis of the susceptibility weighted imaging patterns in malignant brain tumors during antiangiogenic treatment: technical report on four cases serially imaged by 7 T magnetic resonance during a period of four weeks.

Authors:  Antonio Di Ieva; Christian Matula; Fabio Grizzi; Günther Grabner; Siegfried Trattnig; Manfred Tschabitscher
Journal:  World Neurosurg       Date:  2011-11-07       Impact factor: 2.104

8.  Three-dimensional susceptibility-weighted imaging at 7 T using fractal-based quantitative analysis to grade gliomas.

Authors:  Antonio Di Ieva; Sabine Göd; Günther Grabner; Fabio Grizzi; Camillo Sherif; Christian Matula; Manfred Tschabitscher; Siegfrid Trattnig
Journal:  Neuroradiology       Date:  2012-08-18       Impact factor: 2.804

9.  Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma.

Authors:  Teri N Kreisl; Lyndon Kim; Kraig Moore; Paul Duic; Cheryl Royce; Irene Stroud; Nancy Garren; Megan Mackey; John A Butman; Kevin Camphausen; John Park; Paul S Albert; Howard A Fine
Journal:  J Clin Oncol       Date:  2008-12-29       Impact factor: 44.544

10.  Added value and diagnostic performance of intratumoral susceptibility signals in the differential diagnosis of solitary enhancing brain lesions: preliminary study.

Authors:  H S Kim; G-H Jahng; C W Ryu; S Y Kim
Journal:  AJNR Am J Neuroradiol       Date:  2009-05-20       Impact factor: 3.825

View more
  2 in total

1.  [Towards more precision in the therapy of brain tumors. Possibilities and limits of MRI].

Authors:  A Radbruch; E Hattingen
Journal:  Nervenarzt       Date:  2015-06       Impact factor: 1.214

Review 2.  Advanced MR Imaging in Neuro-oncology.

Authors:  A Radbruch; M Bendszus
Journal:  Clin Neuroradiol       Date:  2015-07-29       Impact factor: 3.649

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.